Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

1.8K
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and...
1.8K
Vaccinations01:51

Vaccinations

52.9K
Overview
52.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Induction of SpCas9-Directed Immune Responses Using Lipid Nanoparticles and Identification of SpCas9-Derived T Cell Epitopes in C57BL/6 Mice.

The CRISPR journal·2026
Same author

Azide-functionalized SpCas9 enables generation of site-selective and bioactive Cas9-siRNA conjugates.

Chemical communications (Cambridge, England)·2026
Same author

Vaccination with cationic liposome-encapsulated CD4 and CD8 T cell neoepitopes induces superior tumor control.

Materials today. Bio·2026
Same author

Magnetic Lipid Nanoparticles for Targeted mRNA Delivery and Enhanced Organ-Specific Expression.

ACS applied materials & interfaces·2026
Same author

LAH5-mediated delivery of prime editor ribonucleoprotein complexes for genome editing.

International journal of pharmaceutics·2026
Same author

Detailed Splenic Single-Cell Biodistribution of Phosphatidylglycerol-Containing Liposomes.

Molecular pharmaceutics·2026

Related Experiment Video

Updated: Mar 8, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

2.3K

Self-Assembling Peptide Epitopes as Novel Platform for Anticancer Vaccination.

Mazda Rad-Malekshahi1,2, Marieke F Fransen3, Małgorzata Krawczyk1

  • 1Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Utrecht, The Netherlands.

Molecular Pharmaceutics
|January 17, 2017
PubMed
Summary

Novel self-assembling peptide epitopes (SAPEs) enhance peptide vaccine immunogenicity by forming nanostructures. These SAPEs effectively stimulate CD8+ T cells and show promise in delaying tumor growth, warranting further clinical development.

Keywords:
human papillomavirus (HPV)immunotherapynanoparticlesovalbumin (OVA)self-assembling peptide epitopestherapeutic cancer vaccine

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K

Related Experiment Videos

Last Updated: Mar 8, 2026

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo
07:33

Preparation, Characteristics, Toxicity, and Efficacy Evaluation of the Nasal Self-Assembled Nanoemulsion Tumor Vaccine In Vitro and In Vivo

Published on: September 28, 2022

2.3K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.8K
Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells
12:43

Generation of a Novel Dendritic-cell Vaccine Using Melanoma and Squamous Cancer Stem Cells

Published on: January 6, 2014

12.3K

Area of Science:

  • Biotechnology
  • Immunology
  • Materials Science

Background:

  • Peptide epitope vaccines show potential but face challenges like poor antigen loading and premature epitope release.
  • Nanoparticulate delivery systems can enhance immune responses to peptide antigens compared to soluble forms.
  • T cell anergy is a risk with current peptide vaccine delivery systems.

Purpose of the Study:

  • To improve the immunogenicity of peptide epitope vaccines.
  • To develop novel nanocarriers using self-assembling materials for enhanced vaccine delivery.
  • To overcome limitations of existing peptide vaccine delivery systems.

Main Methods:

  • Developed self-assembling peptide epitopes (SAPEs) by conjugating self-assembling peptides or thermosensitive polymers to peptide antigens.
  • Characterized SAPE nanostructures (20-200 nm diameter).
  • Evaluated SAPE immunogenicity in mice, including CD8+ T cell induction and expansion, with CpG adjuvant.

Main Results:

  • SAPEs successfully formed nanostructures.
  • SAPEs adjuvanted with CpG induced and expanded antigen-specific CD8+ T cells.
  • Mice vaccinated with HPV E743-57 peptide-harboring SAPEs exhibited delayed tumor growth and increased survival.

Conclusions:

  • Self-assembling peptide based systems significantly increase the immunogenicity of peptide epitope vaccines.
  • SAPEs demonstrate potential for therapeutic applications, particularly in cancer immunotherapy.
  • These findings support further development of SAPEs for clinical use.